Breast cancer patients had significantly higher serum SEMA4C levels than patients with benign breast tumor and normal controls. Serum SEMA4C is considered as a candidate diagnostic biomarker for the early detection and diagnosis of breast cancer.

An overview of the efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC patients with EGFR mutation. We also focused on the mechanisms that affect the efficacy of ICIs in patients with EGFR mutation and further investigation worth to be done in future.

In recent years, immunotherapy has been considered the most promising method to overcome cancer and extend survival. It has been widely reported in preclinical and clinical studies that radiotherapy induces immunomodulatory effects by releasing TAAs and activating immunoregulation-related signaling pathways, initiating tumor-specific cytotoxic T cells, and promoting T cells to enter into tumor tissues. In this manuscript, we summarize the current status of immunotherapy and iRT and the development and additional combination strategies to enhance the efficacy of iRT.

Our results identified that MAGE-C3 promotes tumor metastasis not only through the EMT but also by protecting tumors from immunosurveillance

This review discusses molecular traits and recent ER-low positive breast cancer innovations, highlighting molecular-targeted treatment rather than traditional unified endocrine therapy for future basic and clinical research.

The present study showed that nuclear AURKA rather than its kinase activity induced PD-L1 expression via a MYC-dependent pathway. In addition, downregulation of AURKA led to increased CD8⁺ T cell infiltration and activation in vivo. Thus, our data provided evidences for the involvement of AURKA in immune evasion of triple-negative breast cancer.

This study demonstrated similarity between LY01008 and reference bevacizumab (Avastin) in terms of efficacy, safety, and immunogenicity in combination with paclitaxel and carboplatin as first-line treatment in Chinese patients with advanced non-squamous NSCLC.

Universal endoscopy screening is recommended for all aged 40-69 years in high-risk areas of China to control esophageal squamous cell carcinoma (ESCC). This study estimated risk-stratified endoscopic (RSES) strategies based on a previously developed ESCC prediction model in a representative Chinese population from high-risk areas. RSES would be a feasible strategy to optimize the current universal endoscopic screening strategy in high-risk areas by increasing efficiency and decreasing screening costs.